Study of Intermittent OSI-906 Dosing

ABSTRACT: Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.

DISEASE(S): Ovarian Cancer,Non-small Cell Lung Cancer,Colorectal Cancer,Advanced Solid Tumors,Advanced Cancer,Breast Cancer

PROVIDER: 2043067 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR